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Abstract
Background: Gene expression profiling is moving from the research setting to the practical
clinical use.
Gene signatures able to correctly identify high risk breast cancer patients as well as to predict
response to treatment are currently under intense investigation. While technical issues dealing with
RNA preparation, choice of array platforms, statistical analytical tools are taken into account, the
tissue collection process is seldom considered.
The time elapsed between surgical tissue removal and freezing of samples for biological
characterizations is rarely well defined and/or recorded even for recently stored samples, despite
the publications of standard operating procedures for biological sample collection for tissue banks.
Methods: Breast cancer samples from 11 patients were collected immediately after surgical
removal and subdivided into aliquots. One was immediately frozen and the others were maintained
at room temperature for respectively 2, 6 and 24 hrs. RNA was extracted and gene expression
profile was determined using cDNA arrays. Phosphoprotein profiles were studied in parallel.
Results: Delayed freezing affected the RNA quality only in 3 samples, which were not subjected
to gene profiling. In the 8 breast cancer cases with apparently intact RNA also in sample aliquots
frozen at delayed times, 461 genes were modulated simply as a function of freezing timing. Some
of these genes were included in gene signatures biologically and clinically relevant for breast cancer.
Delayed freezing also affected detection of phosphoproteins, whose pattern may be crucial for
clinical decision on target-directed drugs.
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Conclusion: Time elapsed between surgery and freezing of samples appears to have a strong
impact and should be considered as a mandatory variable to control for clinical implications of
inadequate tissue handling.
Background
Our understanding of the underlying molecular mecha-
nisms in various human tumors has increased exponen-
tially over the last decades due to the rapid development
and application of technologies such as DNA microarrays
and mass spectrometry-based proteomics. DNA microar-
ray technology has markedly contributed to the compre-
hension of the complexity of pathways governing
aggressiveness and treatment response of human neopla-
sias [1]. Further developments are expected as techniques
are improving and allow the use of tiny amounts of tissue
both frozen or even fixed and paraffin-embedded for
comprehensive molecular analyses [2].
When comparing results from published microarray stud-
ies, differences in patient cohorts, treatment regimens,
type of gene expression platform employed are usually
taken into account, while procedures and timing related
to the processes encompassed between surgical excision
and freezing and/or fixation of the biological samples are
poorly controlled. Such procedures, applied during sam-
ple handling may however significantly affect microarray
data. In particular ischemia combined with room temper-
ature storage due to the prolongation of the time elapsed
between surgical removal and snap-freezing in liquid
nitrogen is likely to alter gene expression patterns [3] as
well as protein expression [4]. If this is the case the gene
expression data may be modified by an external source of
variability, and consequently represent the result of a
complicated interplay between disease-associated gene
and conditions of sample handling rather than a specific
disease condition.
Despite the definition of strict operating procedures for
collection of samples in tissue banks [5], pre-analytical
procedures have been scarcely ever controlled during the
daily routine. Such pre-analytical variation is probably
not likely to impact results from comprehensive genome-
wide profiling studies designed to select or discover genes
linked to a particular pathological condition. In fact when
employing whole genome arrays the pre-analytical noise
may be compensated by the large number of investigated
transcripts. However, in the case of validation of signa-
tures or even more in the case of their use for clinical deci-
sion, according to FDA-approved commercially available
tests as the OncoDx™ (Genomic Health, Redwood City,
CA) and the MammaPrint® (Agendia, Netherlands), it is
very important to try to build gene signatures containing
robust genes not affected by handling procedures and
therefore to define which are the genes particularly prone
to be modified by inadequate pre-analytical processing.
Indeed the effect of inappropriate tissue handling is a crit-
ical issue not only for frozen samples, but also for fixed
samples where the elapsed time between surgical removal
and fixation adds technical variability to the possible
alterations induced by fixation procedure.
Some studies have already addressed the issue in a
number of human, rat and mouse tissues. Using real-time
RT-PCR quantification in mouse liver specimens, Almeida
et al [3] assessed the expression of six genes and showed
their modulation under ischemic conditions both at two
different temperatures mimicking surgical ischemic con-
ditions and at room temperature waiting time prior to
pathological examination. Similarly using cDNA microar-
rays three separate groups, Huang [6], Blackhall [7] and
Dash [8], analyzed respectively specimens from a human
colon normal mucosa sample, a couple of lung tumors
and four prostate samples. All these studies disclosed dif-
ferential gene expression patterns related to delays in tis-
sue processing. Miyatake et al [9] drew the same
conclusion investigating the effects of ischemia in differ-
ent tissues of rat (lung, liver, kidney and spleen). In addi-
tion, the authors demonstrated a tissue-dependent
transcriptional response against warm ischemia stressing
this way the importance of homogeneous surgical proce-
dures for result comparison.
Breast tumors have been extensively profiled by gene
expression analysis and encouraging data are available
both in the area of prognosis and treatment response pre-
diction [10]. In order to gain awareness of the gene expres-
sion artifacts linked to improper tissue handling also for
this particular type of neoplasia, we have investigated
gene expression profiles in a set of primary breast tumors,
grossly subdivided into 4 aliquots and kept at room tem-
perature for 0, 2, 6 and 24 hours after resection before
snap-freezing in liquid nitrogen. In addition, we concom-
itantly explored the time-related preservation of tyrosine
phosphorylated proteins, considered to be crucial in can-
cer development and directly implicated on target-
directed therapeutics. Our results show that elapsed time
between surgery and freezing has a strong effect on func-
tional genomic analysis and may affect the expression of
genes relevant for predictive signatures as well as the phos-
phorylation status of molecular targets. Therefore pre-ana-
lytical conditions should be taken into account as a
separate variable both when designing and interpretingBMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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comprehensive molecular analyses on archival speci-
mens.
Methods
Case material
Eleven histologically confirmed primary breast tumors
were obtained from the Tissue Bank of the Fondazione
IRCCS Istituto Nazionale Tumori between October 2006
and March 2007. For each sample a written informed con-
sent signed by the patient was available authorizing the
use of leftover material for research purposes. The study
was approved by Independent Ethics Committee and
Institutional Review Board. Samples used in the study
were selected based on the size, carefully avoiding
necrotic areas, fat and normal tissue. An adjacent section
was stained and used for defining the percentage of tumor
cells. Only specimens with more than 70% of tumor cells
were included in the study. Each tissue sample was
divided into 4 aliquots. One was immediately frozen
while the remaining three were frozen after 2, 6 and 24
hours at room temperature.
RNA isolation and expression profiling
Tissue was pulverized using a Mikrodismembrator (Braun
Biotech International, Germany). Total RNA was extracted
with the Trizol reagent (Invitrogen, Carlsbad, CA) accord-
ing to manufacture instructions and an additional DNase
digestion was performed using the RNeasy kit (Qiagen,
Valencia, CA). After each extraction a small fraction of
RNA was used for quality and yield assessment. RNA total
concentration and purity were determined by UV spec-
trometry. Total RNA electrophoretic profile was analysed
by the Agilent RNA 6000 NanoLabChip kit on the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA)
using the software provided by the manufacturer for deter-
mination of RIN (RNA integrity number).
Probe labelling and hybridization were performed as pre-
viously described [11]. The samples and a reference RNA
(Universal Human Reference RNA, Stratagene, La Jolla,
CA) were labelled directly with Cy3-dCTP (reference
RNA) or Cy5-dCTP (sample RNA) (Amersham Bio-
sciences, Little Chalfont, UK) and indirectly with 3DNA
Submicro Expression Array Detection kit (Genisphere,
Montvala, NJ). Hybridization was carried out in a hybrid-
ization station (Genomic Solutions, Ann Arbour, MI),
slides were scanned using the GenePix 4000B microarray
scanner and quantified using GenePix Pro 5.0.1.24 (Axon
Instruments/Molecular Devices). The RNAs were hybrid-
ized on two different cDNA microarrays containing a total
of 17172 unique clones selected from the Human
sequence-verified I.M.A.G.E. clone collection (Research
Genetics/Invitrogen, Carlsbad, CA) and spotted in tripli-
cate. Raw gene expression data have been deposited at the
European Bioinformatics Institute (EBI) ArrayExpress and
are accessible through accession no. E-MEXP-2035.
Quantitative real-time PCR
Total RNA isolated for the microarray analysis was used to
verify the quantity of specific messengers by real-time PCR
for 4 biologically relevant differentially expressed genes
(i.e., FGFR4, ESR1, ERBB2, FBLN2). RNA was reverse tran-
scribed using the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). Samples were
amplified in multiplex PCR reactions using one of the
assays of interest labelled with FAM. PPIA was used as
housekeeping gene. Reactions were performed in a final
reaction volume of 20 μl containing cDNA template, 10 μl
2× TaqMan Gene Expression Assay (Applied Biosystems,
Foster City, CA) and thermal cycling was performed on an
ABI PRISM 7700 Sequencer Detector (Applied Biosys-
tems, Foster City, CA).
Protein Profile Analysis
Following tissue pulverization, tumor samples were proc-
essed as described in [12]. Briefly, samples were lysed in
an ice-cold buffer containing 50 mM HEPES (pH 7.6),
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM
MgCl2, 1 mM EGTA, 10 mM Na4P2O7, 100 mM NaF, pro-
tease inhibitors and in presence or absence of 1 mM
sodium orthovanadate. After 30 min incubation with gen-
tle rocking at 4°C, lysates were cleared by centrifugation
(10 min at 13,000 rpm). Supernatants were collected and,
after protein concentration determination, tested for the
presence of specific proteins by Western blotting. For
Western blotting, cell lysates were resolved by 4-12% SDS-
PAGE (precast gel NuPAGE, Invitrogen). Proteins were
transferred to nitrocellulose membranes (Hybond-C
Super, Amersham Bioscience, Little Chalfont, UK),
checked for equal sample loading by Red Ponceau S stain-
ing, and probed with the appropriate antibodies. Immu-
noreactive bands were visualized using horseradish
peroxidase-linked secondary antiserum (Amersham Bio-
sciences, Little Chalfont, UK) and detected using an
enhanced ECL system (Amersham Biosciences, Little
Chalfont, UK). For Western blotting, the following anti-
bodies were used: anti-p-Tyr 4G10 (Upstate Biotechnol-
ogy, Millipore Corporation, Billerica, MA); p-Neu (Tyr
1248)-R (Santa Cruz, Biothecnology, Santa Cruz, CA) for
ERBB2 and anti-FAK (Transduction Laboratories, BD,
Franklin Lakes, NJ).
Data analysis and Statistics
Raw microarray images and quantifications were stored
and processed in Bio Array Software Environment (BASE,
Lund Sweden) [13]. Poor signal quality of background-
corrected Cy3 and Cy5 intensities were flagged and a low-
ess normalization [14] was applied to each slide. Repli-BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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cated spots were averaged and their log (base2) expression
ratios (tumor/reference) were downloaded from BASE
and imported into BRB-ArrayTools version 3.4.0.
(Bethesda, MD) developed by Richard Simon and Amy
Peng Lam [15]. ANOVA analysis was performed following
their instructions. All I.M.A.G.E clones annotations were
updated with the latest release of NCBI Unigene (Build
No. 194) using SOURCE[16]. In order to find the overlap
between our list of genes and genes included in public
available signatures, we employed the Merge function of
the web-application MatchMiner [17]. Hierarchical clus-
tering was performed using centered correlation and aver-
age linkage method.
For gene function analyses, a score obtained calculating
the -Log(p-value) of the Fisher Exact Test indicates the
probability that a function is obtained by chance; scores
equal or greater than 3 give a 99.9% confidence level of
not being generated by chance.
The genes identified by microarray analyses were chal-
lenged for gene function. After having imported their
accession numbers into the Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems, Mountain View, CA),
they were categorized according to the gene functions
present in the database.
Data analysis for real-time PCR was done using the
Sequence Detector version 1.9 software. Relative log-
expression of the genes (-ΔCt) was obtained subtracting
the number of cycle threshold observed for the 18S gene
from that observed for the gene of interest. After being
exported further data analysis was performed in a
BRB_ArrayToolv3.4.0.
The association between gene expression evaluated by
cDNA microarry and real-time PCR was evaluated by lin-
ear regression analysis.
Results and Discussion
Gene expression analysis
The number of clinical reports dealing with gene expres-
sion profiling in human breast cancer has enormously
increased, but little research has been performed to evalu-
ate the variability due to sampling of surgical specimens,
and no information has been generally provided about
the time elapsed between surgical excision and tissue
freezing. We addressed the problem by investigating on
11 individual breast tumors, whose clinico-pathological
characteristics are shown in Table 1, the gene expression
profile of 4 serial samples frozen at different time intervals
from surgical resection.
The evaluation of RNA showed a time dependent decrease
of 28S and 18S ribosomal bands and a trend towards
lower RIN numbers for samples stored for longer times at
room temperature. Two examples are shown in Fig. 1, one
with limited and one with more extended RNA degrada-
tion. Overall, for 8 breast cancers the serial samples
showed valuable results, i.e., RNA not degraded (RIN>5)
after prolonged exposure of samples to room tempera-
ture, and these cases were submitted to gene expression
analysis [18,19]. Unsupervised hierarchical clustering
analysis showed that samples belonging to the same
patient tended preferentially to cluster together (Fig. 2),
highlighting the patient-specific gene expression features
despite different tissue freezing times. In fact only in 3 of
the 8 samples (Pb6, Pb3 and Pb5) aliquots frozen at dif-
ferent times clustered separately.
Notwithstanding the relatively limited RNA degradation,
a time-dependent modulation of genes was observed in
the different serial aliquots, likely expected as a cellular
reaction to stress conditions following the surgical resec-
tion of blood vessels and the suboptimal pre-analytical
conditions. The gene expression profile of these serial
specimens was performed using cDNA arrays containing
Table 1: Clinico-pathological characteristics of samples
ID ER status* PR status§ ERBB2 status^ Age Size (cm) N status
Pb1 + + 2+ 69 6 +
Pb2 + + 2+ 85 7 -
Pb3 + + 2+ 30 2.5 +
Pb4 + + 2+ 46 1.1 -
Pb5 + + 3+ 58 2.0 +
Pb6 + + - 55 2.0 +
Pb7 + + 2+ 57 3.0 +
Pb8 - - - 40 4.0 -
Pb9 + + 1+ 43 6.0 +
Pb10 + + - 54 2.2 -
Pb11 + - - 80 5.5 -
*determined by ER-ICA
§determined by PgR-ICA
^determined by Hercept test (DAKO)BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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17,172 unique clones and analyzed by the ANOVA
model. Using such approaches, genes whose modulation
varied over the time independently of the intrinsic
patient-specific differences were disclosed. A separate
ANOVA model at significant threshold of p < 0.01 was fit-
ted for each gene to relate the log-ratios expression to the
factors under investigation (i.e. the time points and the
different patients, the latter considered as blocking fac-
tor). Our results pointed out a significant variation as a
function of time. Considering the number of genes mod-
ulated at each single time point compared to the sample
immediately frozen as baseline, we noticed an increase in
the number of modulated genes especially after 24 hours:
121 genes (0.76% of genes present in our chip) were mod-
ulated after 2 hours (66/121 were up-regulated); 157
genes (0.98%) were modulated after 6 hours (110/157
were up-regulated), 657 genes (4.1%) were modulated
after 24 hours (287/657 were up-regulated) following tis-
sue resection. Moreover, taking into account the overall
time course of gene expression, we found 461 genes regu-
lated at the significant threshold of p < 0.01, representing
2.88% of genes present in our chip. Around 1.03% of 461
genes were expected to be false positives according to the
multiple testing correction method of Benjamini-Hoch-
berg [20].
RNA quality check Figure 1
RNA quality check. RNA electropherograms obtained by running 250 ng of total RNA from aliquots of two representative 
samples on a 2100 Bioanalyzer with the RNA 6000 Nano LabChip. Elapsed time between surgical removal and freezing in liquid 
nitrogen is reported along with the RIN value. Each electropherogram reports fluorescence units as a function of running sec-
onds.BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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This result is in keeping with published data [3,4,6-9] in
which a certain degree of gene expression variation as a
function of collection procedures is reported. However,
the modulation we noticed in breast cancer specimens
was not as remarkable as the one reported by in Spruessel
et al [4], where 20% of all detectable genes are modulated
after 30 minutes of colon resection. In our study the
majority of the genes (about two-thirds) were down-regu-
lated, and up-regulated genes represented less than 1% of
all the genes in our chip. Similarly Dash et al reported less
than 0.6% of over-expressed genes in their study on radi-
cal prostatectomy specimens [8].
To better assess the impact of sample handling on the
expression of critical genes, some of the modulated genes
with an established biological role in breast cancer were
subjected to a technical validation by qPCR. The statisti-
cally significant correlations between expression evalu-
ated by cDNA microarray and Real Time PCR for FGFR4 (r
= 0.57, p = 0.0008), FBLN2 (r = 0.595, p = 0.0004), ESR1
(r = 0.87, p = 0.0000008), ERBB2 (r = 0.754, p =
0.000002) clearly supports the fact that such a modula-
tion is not imputable to technical artifacts, but represents
a real biological phenomenon.
Effect of sample collection procedure on gene pathways
The 461 genes modulated as a function of delayed freez-
ing of samples were analyzed using the IPA tool to under-
stand if they were representative of specific biological
categories. We focused our attention on the twelve most
significant gene functions (Fig 3) that contain 69.6% of all
genes which were present in the IPA database. Inflamma-
tory, immunological disease, and cell cycle were the most
significantly enriched gene classes. Globally various genes
crucial for breast cancer were included. Among them,
PIK3CD (p110δ) which is a catalytic subunit member of
the class IA PI3K heterodimer, a signal transduction
enzyme that regulates a broad spectrum of cellular func-
tions as cell growth, proliferation and ultimately survival
[21]. Inhibition of PIK3CD activity reduces VEGF activity
leading to lack of vascular permeability [22]. As survival
pathways play a crucial role both in prognostic outcome
of breast cancer as well as in affecting treatment sensitiv-
ity, an artifact induction of such genes could be dramati-
Hierarchical clustering of all samples at different freezing times Figure 2
Hierarchical clustering of all samples at different freezing times. Hierarchical clustering of the gene expression matrix 
containing no missing values of 4 different aliquots derived from 8 individual samples. The dendrogram for clustering was 
obtained using centered correlation and average linkage. Patient ID and time elapsed between surgical removal and freezing are 
reported for each sample.
Patient ID
Time (h)
Sample IDBMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
Page 7 of 14
(page number not for citation purposes)
cally misleading. Similarly, among the genes down-
regulated, STAT1 transcription was found repressed
because of hypoxia mediated by HIF-1 and STRA13 [23].
CD44 was also among the down-regulated genes. This
gene encodes a cell surface receptor for hyaluronate and is
a direct target of miR373/miR520c, two recently identified
metastasis-promoting microRNAs in breast cancer [24].
CD44 expression is associated with increased survival in
node negative breast cancer [25] and decreased metastatic
invasion [26].
Also genes reported to be associated with response to anti-
estrogen were found to be down-regulated by delayed tis-
sue processing. Among them FBLN2, a gene reported to be
up-regulated in elderly breast cancer patients who are not
responsive to pre-operative treatment with toremifene
[11] and FGFR4 whose up-regulation predicts poor
response to tamoxifen [27]. Results are reported in Fig 4
panel A.
Comparison with published breast cancer microarray 
studies
The use of gene signatures for predicting prognosis and
response to treatment is quickly moving from a research
area to the clinical practice. The reliability of such tools as
well as they performance are strictly related to accurate
Significantly enriched biological categories Figure 3
Significantly enriched biological categories. Chart of the most significantly enriched biological categories as identified 
with Ingenuity. For each category -log(p value) and number of genes are reported.BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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gene expression determination which could be affected by
sample handling and storage. To better understand to
which extent commonly used signatures in breast cancer
could be affected by artifacts linked to sample handling
we verified how many of our 461 genes were included in
such gene lists [2,28-33].
Results are reported in Table 2. No common genes were
found between our 461 genes modulated by tissue han-
dling conditions, two clinically relevant lists of genes
associated to grading [29,31] and with the 70-gene classi-
fier [32]. Conversely 28 genes were included in the intrin-
sic gene list [28], 24 in the wound healing gene list [27]
and 17 genes were included in the new 1300-intrinsic
Hierarchical clustering of all samples using literature signatures Figure 4
Hierarchical clustering of all samples using literature signatures. The number of genes common between our data set 
and each specific signature is reported in brackets. The dendrogram for clustering was obtained using centered correlation and 
average linkage. Patient ID and time elapsed between surgical removal and freezing are reported for each sample. The stability 
of our clusters (at a correlation level r>0.2) was investigated exploiting a BRB algorithm which performs 100 permutations of 
data and calculates an R index ranging between 0 and 1 where 0 indicates non reproducibility and 1 complete reproducibility. R 
index values are reported for each single clustering result.
Chang et al. (343) Sorlie et al. (271)
van’t Veer et al. (19) Wang et al. (27)
Ivshina et al. (10) Paik et al. (8)
R = 0.78
R = 0.55
R = 0.98
R = 0.69
R = 0.58
R = 0.67BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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Table 2: Genes common with main breast cancer genes signatures
28 genes common with the intrinsec genes list (Sorlie et al.)
P value Gene symbol Descriptor
0.0003 FGFR4 Fibroblast growth factor receptor 4
0.0007 SELENBP1 Selenium binding protein 1
0.0010 POSTN Periostin, osteoblast specific factor
0.0010 CALU Calumenin
0.0012 SERPINH1 Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)
0.0012 KDELR3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
0.0013 PTMS Parathymosin
0.0013 HIST2H2BE Histone 2, H2be
0.0015 TUSC3 Tumor suppressor candidate 3
0.0016 ZNF516 Zinc finger protein 516
0.0018 BMI1 Polycomb group ring finger 4
0.0024 ACAD11 Putative acyl-CoA dehydrogenase
0.0026 INPP4B Inositol polyphosphate-4-phosphatase, type II, 105 kDa
0.0033 ESR1 Estrogen receptor 1
0.0037 ACAA2 Myosin VB
0.005 CYB5A Cytochrome b-5
0.005 CLIP4 CAP-GLY domain containing linker protein family, member 4
0.0051 AYTL1 Hypothetical protein FLJ20481
0.0056 RALGPS1 Ral GEF with PH domain and SH3 binding motif 1
0.0062 PSMB10 Proteasome (prosome, macropain) subunit, beta type, 10
0.0067 LRBA LPS-responsive vesicle trafficking, beach and anchor containing
0.0070 UBE1 Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)
0.0084 FBP1 Fructose-1,6-bisphosphatase 1
0.0087 COL6A3 Collagen, type VI, alpha 3
0.0087 TM9SF2 Transmembrane 9 superfamily member 2
0.0090 TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
0.0097 DIP2B KIAA1463 protein
0.0100 TncRNA Trophoblast-derived noncoding RNA
24 genes common with wound healing signature (Chang et al)
0.0038 EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1
0.0086 PRIM2 primase, polypeptide 2A, 58 kDa
0.0021 POR P450 (cytochrome) oxidoreductase
0.0002 FANCG Fanconi anemia, complementation group G
0.0097 EXOSC7 Exosome component 7
0.0006 FDPS Farnesyl diphosphate synthase 
(farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)
0.0020 C5orf4 Chromosome 5 open reading frame 4
0.0055 CDCA4 Cell division cycle associated 4
0.0099 H2AFV H2A histone family, member V
0.0061 FABP3 Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)
0.0027 CKLF Chemokine-like factor
0.0014 MGC4308 Hypothetical protein MGC4308
0.0009 FADS1 Fatty acid desaturase 1
0.0061 SFTPB Surfactant, pulmonary-associated protein B
0.0055 PLA2R1 Phospholipase A2 receptor 1, 180 kDa
0.0007 SELENBP1 Selenium binding protein 1
0.006 FARSB Phenylalanine-tRNA synthetase-like, beta subunit
0.0054 MEF2D MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)
0.0029 NUTF2 Nuclear transport factor 2
0.0098 ID3 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein
0.0087 ID2 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
0.0069 PRG2 Proteoglycan 2, bone marrow
0.0001 H2AFX H2A histone family, member X
0.0047 WSB1 WD repeat and SOCS box-containing 1BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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gene list [33] and 2 in the list by Wang et al [34]. Genes
included in such signatures were involved in lipid metab-
olism, transport, and cell proliferation.
We then assumed that the extent of the impact of tissue
handling on the prognostic/predictive reliability of a
given gene signature, could be indirectly evaluated look-
ing at its capability to maintain the clustering of individ-
ual samples collected at different times.
Results are reported in Fig. 4 for various gene signatures.
After clustering the sample aliquots with the genes derived
from the signature of Chang et al (343 genes in common
with our data set) aliquots from 5 of 8 samples clustered
together and similar data were obtained using the signa-
ture of Sorlie et al (271 genes in common), where in 6 out
of 8 samples aliquots collected at different times clustered
together. As expected, clustering of samples using signa-
tures with a low number of genes as that of Paik et al [35],
or with a small number of genes after searching for com-
mon genes within our data set, as that of Ivshina et al [31],
were instead affected by inappropriate tissue handling as
tissue aliquots obtained from the same patient did not
cluster together. This underlines the fact that tissue mis-
handling has a limited effect on signatures with high gene
numbers as already suggested in the Background section.
Interestingly, using the signatures with an intermediate
number of genes (respectively 27 and 19 common genes)
as in the case of the signature by Wang et al [34] and by
van't Veer [32], we still observed that in most samples (5
out of 8 and 4 out of 8, respectively) aliquots from the
same patient obtained at different times, did in fact cluster
together. In these dendrograms the relatively low number
of genes was probably partially compensated by the lack
of overlapping (only 2 overlapping genes with the genes
by Wang et al and none with genes by van't Veer) between
such genes and the 461 genes that we identified as genes
modulated by temperature. This may be an indirect proof
of the fact that our 461 genes may be considered as relia-
ble indicators of tissue mishandling
We also considered the expression of single genes impli-
cated in breast cancer and currently used as predictive
markers in the clinical management (ESR1, ERBB2,
FBLN2, FGFR4, PGR). As reported in Fig 5 independently
of ER base levels, ESR1 was consistently down-regulated
through the four considered time points with the maximal
down-regulation after 24 hours at room temperature. Fig
5 panel B reports the ESR1 microarray intensity expression
for three samples where the effect is more evident (Pb3,
Pb5 and Pb7). A similar down-regulation was observed
for FBLN2 and FGFR4. On the contrary, no significant
modulation was found for ERBB2.
Impact of sample collection procedures on protein profile
In order to set up conditions to study signaling pathways
in post resection specimens, we also explored the effects
of pre-analytical procedures on protein status, examining
tyrosine phosphorylation or expression in Western blot-
ting experiments and time course conditions. We firstly
explored the tyrosine phosphoprotein profiles testing the
17 genes common with new intrinsic gene list (Zhiyan et al.)
0.0033 TRIM33 Tripartite motif-containing 33
0.0003 RAB5C RAB5C, member RAS oncogene family
0.0086 PRIM2 primase, polypeptide 2A, 58 kDa
0.0071 RAB21 RAB21, member RAS oncogene family
0.0029 SSTK Serine/threonine protein kinase SSTK
0.0001 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
0.0052 IRF4 Interferon regulatory factor 4
0.0067 LRBA LPS-responsive vesicle trafficking, beach and anchor containing
0.0036 IL13RA1 Interleukin 13 receptor, alpha 1
0.0033 ESR1 Estrogen receptor 1
0.0017 MFAP2 Microfibrillar-associated protein 2
0.0031 STAT1 Signal transducer and activator of transcription 1, 91 kDa
0.0013 PPFIA1 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1
0.0061 MYO1C Myosin IC
0.0082 PPFIA4 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4
0.0060 RAB31 RAB31, member RAS oncogene family
0.0026 INPP4B Inositol polyphosphate-4-phosphatase, type II, 105 kDa
2 genes common with Recurrence Score genes (Paik et al)
0.0033 ESR1 Estrogen receptor 1
0.0021 MMP11 Matrix metalloproteinase 11 (stromelysin 3)
Table 2: Genes common with main breast cancer genes signatures (Continued)BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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reactivity to antiphosphotyrosine antibody on total
extracts of 2 serial samples from a breast cancer specimen
(Pb2, Pb3) frozen at different times from surgery and
obtained in absence or in presence of orthovanadate, a
phosphatase inhibitor. Results are shown for Pb3 taken as
a representative sample in Fig 6A. With the addition of
orthovanadate in lysis buffer, the loss of phosphotyrosine
proteins due to delayed freezing was clearly prevented up
to 6 hours. However, after 24 hours at room temperature
no major differences were observed between the pattern
of phosphoproteins in the presence and in the absence of
orthovanadate. These results provide the information that
phosphatase inhibition is not sufficient to stabilize pro-
tein phosphorylation at room temperature. We then per-
formed time course experiments on other two serial
samples from breast cancers (Pb1 and Pb2) lysed in pres-
ence of orthovanadate (Fig 6B). Antiphosphotyrosine
hybridization results highlighted the progressive loss of
phosphoproteins during time course with individual var-
iability probably depending on which specific phospho-
protein pathways become activated or suppressed ex vivo.
Detection of phosphoepitopes is often very important for
understanding whether a specific pathway is active, thus
inadequate pre-analytical procedure may dramatically
modify biological interpretation of data obtained on clin-
ical samples. Therefore sample Pb1 and Pb2, for which
ERBB2 immuhistochemistry positivity was detected
(Table 1) and gene expression analysis showed no signifi-
cant change as a function of the time delay in freezing,
were tested in Western blotting for the level of Tyr 1248
phosphorylation of ERBB2 using a phospho-specific anti-
body (Fig 6C). The result was the same for both tumor
specimens: signal decreased until disappearing within 24
hours post resection. When an anti-FAK antibody was
used to representatively testing protein integrity during
time course, it was found that the signal intensity disap-
peared at 24 hours of incubation (Fig 6C). Still consider-
Expression of selected genes as a function of time Figure 5
Expression of selected genes as a function of time. Panel A. Time course of ESR1, FBLN2, FGFR4 and ERBB2 expression 
for the three specimens (Pb3, Pb5 and Pb7). ESR1, FBLN2, FGFR4 are significantly down-modulated both in microarray and 
qPCR data. Panel B. Time course of ESRI microarray expression data for three samples with different basal ESR1 levels.BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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ing Western blotting a non-quantitative assay it is clear
that at 24 hours time point protein degradation was max-
imal.
Conclusion
The great opportunities offered by the development of the
microarray technology have fueled many studies in cancer
and more are underway exploiting proteomic tools.
Unfortunately, when taking into consideration the relia-
bility of results many factors are usually considered, eg.
sample size, treatment homogeneity, type of follow up,
while pre-analytical conditions are often neglected. In this
study we demonstrate that the likelihood to detect tran-
scriptional differences as well as protein patterns reflect-
ing the biology of samples may be affected by a correct
tissue handling.
RNA integrity is not a sufficient proof of a good quality
sample and even in samples with high RIN gene expres-
sion may be affected by delays in freezing and hypoxia.
The stress caused by resection of blood vessels leads in fact
to rapid cellular changes typically activating hypoxia or
apoptotic pathways. Genes included in signatures com-
monly used in breast cancer also may undergo transcrip-
tional modulations linked to sample handling
procedures. If this is the case misleading results may be
Phosphotyrosine profiles as a function of freezing time Figure 6
Phosphotyrosine profiles as a function of freezing time. Time course analysis (0, 2, 6 and 24 hours) of tyrosine phos-
phoproteins of three breast cancers. A. Anti-p-Tyr immunoblot on equal amounts of extracts from sample 1 lysed in absence 
or presence of Orthovanadate (OV); B. Anti-p-Tyr immunoblot on equal amounts of extracts from sample 2 and 3 lysed in 
presence of Orthovanadate; C. Anti-HERB2-Tyr1248(P) and anti-FAK immunoblots of equal amounts of extracts from sample 
2 and 3.BMC Cancer 2009, 9:409 http://www.biomedcentral.com/1471-2407/9/409
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obtained for single samples and probably evaluation of
the performance of a single gene signature may also be
influenced. Interestingly a down-regulation was consist-
ently reported for ESR1, a gene playing a major role in
clinical management of breast cancer. The latter finding
can probably explain why when looking at messenger lev-
els, the so-called ER gene cassettes are more predictive
compared to ER itself [35]. Tissue handling induced mod-
ulations are not only confined to messengers. In fact in
the case of ESR1 itself also protein expression may be
affected by prolonged hypoxia, although both down-reg-
ulations [36-38] and up-regulations have been observed
[39].
Few studies exist on the stability of proteins and phospho-
proteins in tissue after resection and in dependence of pre-
analytical handling. In this study it was taken into account
the dynamic nature of cell protein composition and
potentially of cell signaling in post excision setting. Gen-
erated data are limited to few specimens and further
future in-depth investigation of the fluctuations of protein
signaling and post translational modifications is needed.
Notwithstanding some phosphoprotein profile fluctua-
tions may potentially be due to tissue individuality, our
non-quantitative data are sufficient to support the conclu-
sion that orthovadate addition in lysis buffer is insuffi-
cient to block fluctuations in phosphoprotein profiles and
also the recommendation to freeze tissue within few min-
utes of resection to preserve the state of phosphoproteins.
In fact, the case of ERBB2 showed the a time-related phos-
phorylated status in the absence of significant changes at
messenger level.
In summary all these data demonstrate that taking advan-
tage of the new profiling techniques for designing tailored
treatment strategies is a goal which cannot be achieved
without an accurate standardization of tissue collection
procedures. Tissue collection procedures should therefore
be rigorously defined and controlled to avoid false results
which may negatively affect the clinical outcome when
attempting personalized treatment strategies. The simple
obtainment of good quality RNA samples is not a guaran-
tee for a reliable gene expression profile.
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